in ,

CDC Vax Advisory Panel Signals Skepticism About Additional Boosters

CDC Vax Advisory Panel Signals Skepticism About Additional Boosters
SDI Productions/iStock/Getty Images Plus

Vaccine advisors to the U.S. Centers for Disease Control and Prevention (CDC) seem to be at odds with the agency on whether to recommend people take a second Covid vaccine booster, or fourth dose, out of safety and efficacy concerns about the measure. For immunocompromised Americans, a second booster would actually be a fifth shot, since the CDC recommended last summer that this cohort receive three doses as part of their primary series.

Weeks after the CDC recommended a second booster for people ages 50 and over, its Advisory Committee on Immunization Practices (ACIP) discussed the medical necessity of additional booster doses. If that sounds backwards, it is because it is.

On March 29, the Food and Drug Administration (FDA) authorized a second booster of the mRNA vaccine from either Pfizer-BioNTech or Moderna for people ages 50 and up four months after their first one. The FDA, however, skipped the regular consultation with its Vaccines and Related Biological Products Advisory Committee (VRBPAC), which evaluates vaccines’ safety, efficacy, and appropriate use by reviewing and verifying the data provided by the vaccine’s manufacturer.

That same day, the CDC signed off on the FDA’s action, saying these individuals “may” get a second mRNA booster if they chose to. Much like its sister agency, the CDC announced the recommendation without consulting with its outside advisors from ACIP, who typically hold a public meeting to review the evidence that the shots are indeed needed to preserve public health.

During the ACIP meeting on Wednesday, the advisors focused primarily on the safety of additional mRNA boosters by analyzing real-world data.

As with the primary series of Moderna and Pfizer/BioNTech, myocarditis and pericarditis continue to be the biggest safety signals with the boosters. That risk, however, was lower than with the second dose of these vaccines, the experts noted.

It is remarkable that, concerning Moderna, the risk of myocarditis, or heart inflammation, appears to be off the charts after the primary vaccination.

According to the FDA documents that were used to grant Moderna’s full approval, among males aged 18 to 25, the rate of myocarditis following Moderna’s primary series was 148 per million males vaccinated.

As reported by The New American on the matter,

The CDC’s baseline for myocarditis in males aged 18 to 25 is one to eight cases per year. There are some 30.8 million Americans of both sexes in that age group, so the number of males would be roughly 15.4 million. Using the FDA’s estimate above of 148 per million, if every young man in the age group receives the Moderna shots, 2,280 will likely develop myocarditis.

Notably, young females also increasingly developed myocarditis following mRNA vaccinations, as did men in older age groups, as…

Read Full Story At: The New American

49ers’ Jimmy Garoppolo speaks on Deebo Samuel’s behalf, updates shoulder recovery

49ers’ Jimmy Garoppolo speaks on Deebo Samuel’s behalf, updates shoulder recovery

‘Jackass 4.5’ releasing next month with unseen stunts from ‘Jackass Forever’

‘Jackass 4.5’ releasing next month with unseen stunts from ‘Jackass Forever’